Robinul 5g Powder For Solution For Iontophoresis
€
MercuryPharma
Package leaflet: Information for the user
Robinul® 3g Powder for Solution for Iontophoresis
Glycopyrronium Bromide
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
r MercuryPharma | |
Version No: |
100561/LF/035/04 |
Product Name: |
Robinul Powder |
Pack Size: |
3g |
Component: |
Leaflet |
SKU: |
100561 |
Market: |
UK |
Production Site: |
DALES PHARMACEUTICALS |
Revision No.: |
6 |
Revision Date: |
17/08/2016 |
Revised by: |
PAT |
CRF: |
AMCo.CRF.452.2015 |
PR 5828 |
The product is known by the name above but will be referred to as Robinul Powder throughout the rest of this leaflet.
What is in this leaflet
1. What Robinul Powder is and what it is used for
2. What you need to know before you use Robinul Powder
3. How to use Robinul Powder
4. Possible side effects
5. How to store Robinul Powder
6. Contents of the pack and other information
Robinul Powder contains Glycopyrronium Bromide which belongs to a group of medicines called anticholinergic drugs. Its purpose is to block certain nerve impulses.
Robinul Powder is used for the treatment of excessive sweating from the palms of your hands and soles of your feet.
Do not use Robinul Powder:
• if you are allergic to glycopyrrolate.
• if you suffer from glaucoma (increased pressure in the eye).
• if you are pregnant.
• if you have fungal or other skin infections.
Make sure your doctor knows if you suffer from any of these.
Warnings and precautions
Talk to your doctor, pharmacist or nurse before using Robinul Powder:
• if you are suffering from heart problems, irregular heartbeats or abnormal blood pressure.
• if you have an overactive thyroid gland.
• if you have a blockage in your urinary passages such as bladder or kidneys.
• if you have a lung problem called chronic bronchitis.
Other medicines and Robinul Powder
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. Pregnancy, breast-feeding and fertility
If you are pregnant or breast feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Do not use during pregnancy or breast feeding.
Driving and using machines
Robinul Powder may cause drowsiness. Do not drive or use machines until you are sure this medicine does not affect your ability to drive.
Robinul Powder will be administered to you by a qualified healthcare professional.
Method of administration:
Your doctor will give you Robinul Powder using a technique known as iontophoresis, which enables the drug to be passed through the skin by means of an electric current. Robinul Powder is made into a solution and then poured into a non-metal container with a large piece of sheet metal (known as an anode) used to conduct electricity. The palm of your hand or sole of your foot will be placed in the
Dimension: |
148x210 mm |
Commodity No.: |
F1328 |
Pharma Code: |
N/A |
Core Spec Ref: |
N/A |
DCMF: |
N/A |
Print Colours: |
Black |
Non-Print Colours: |
Cutter |
Tech App. Date: |
11/08/2016 |
Min. Font Size: |
8 pt |
V_ |
y |
C \
REGULATORY AUTHORITY APPROVAL CONFIRMATION
Confirmation that this artwork has been approved by the appropriate market authority (if applicable, e.g. MHRA, HPRA, etc ) and that Mercury Pharma have license approval to distribute this component for sale in the relevant market.
Accept Artwork / Reject Artwork
(Please strike off whichever NOT applicable)
Signature
Name
Date ...............................................................................
V_/
solution and separated from the metal sheet by plastic foam or a layer of lint or a sponge sheet.
At the same time, another limb is placed in a similar container holding luke warm tap water instead of a solution of Robinul Powder. As before, your limb will be shielded from the metal sheet (this time called the cathode) used to conduct electricity by plastic foam or a lint or sponge sheet. The electric current will vary according to your age. Treatment will last about 12 minutes but will depend on your skin tolerance, body weight and size. Only one site will be treated at a time and only two sites will be treated in any one day. Your treatment will not be repeated within seven days but may be repeated later, perhaps varying the treatment, according to your condition.
If you use more Robinul Powder than you should
This is unlikely because the dose will be administered by a healthcare professional. If you suspect you have been given too much, you should tell the doctor immediately.
If you have any further questions on the use of this medicine ask your doctor, pharmacist or nurse.
Like all medicines this medicine can cause side effects, although not everybody gets them.
Consult a doctor straight away if you notice any of the following symptoms - you may need urgent medical treatment:
Swelling mainly of the face, lips or throat which makes it difficult to swallow or breathe, itching and rashes. This could be a sign of a severe allergic reaction or angioedema (frequency not known, cannot be estimated from the available data).
All medicines can cause allergic reactions although serious allergic reactions are rare.
The following side effects have also been reported under the following frequency:
Not known (frequency cannot be estimated from the available data)
• Dry mouth and eating difficulties, such as problems with swallowing
• Blurring of vision
• A rapid heart beat
• Mild discomfort in your tummy
• Difficulty in passing urine
• A mild tingling feeling in the areas which have been recently treated
You should avoid over exertion particularly in hot weather, until any unwanted effects have disappeared. If any of these become serious, or you notice any side effects not listed in this leaflet, please tell your doctor.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
By reporting side effects you can help provide more information on the safety of this medicine
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Robinul Powder contains
The active substance is glycopyrrolate (glycopyrronium bromide) 100%w/w.
There are no other ingredients.
What Robinul Powder looks like and contents of the pack
Robinul Powder is a white crystalline powder.
Each screw top amber bottle contains 3 grams Robinul Powder.
Marketing Authorisation Holder
MercuryPharm Ltd, 4045, Kingswood Road, City West Business Park, Co Dublin, Ireland.
Manufacturer
Dales Pharmaceuticals Limited, Snaygill Industrial Estate, Keighley Road, North Yorkshire, Skipton, BD23 2RW, United Kingdom.
This leaflet was last revised in August 2016.
MercuryPharm Ltd is licensed to use the registered trademark
100561/LF/035/04 F1328
r MercuryPharma | |
Version No: |
100561/LF/035/04 |
Product Name: |
Robinul Powder |
Pack Size: |
3g |
Component: |
Leaflet |
SKU: |
100561 |
Market: |
UK |
Production Site: |
DALES PHARMACEUTICALS |
Revision No.: |
6 |
Revision Date: |
17/08/2016 |
Revised by: |
PAT |
CRF: |
AMCo.CRF.452.2015 |
PR 5828 |
Dimension: |
148x210 mm |
Commodity No.: |
F1328 |
Pharma Code: |
N/A |
Core Spec Ref: |
N/A |
DCMF: |
N/A |
Print Colours: |
Black |
Non-Print Colours: |
Cutter |
Tech App. Date: |
11/08/2016 |
Min. Font Size: |
8 pt |
V_ |
y |
C \
REGULATORY AUTHORITY APPROVAL CONFIRMATION
Confirmation that this artwork has been approved by the appropriate market authority (if applicable, e.g. MHRA, HPRA, etc ) and that Mercury Pharma have license approval to distribute this component for sale in the relevant market.
Accept Artwork / Reject Artwork
(Please strike off whichever NOT applicable)
Signature
Name
Date ...............................................................................
V_/